<DOC>
	<DOCNO>NCT00466167</DOCNO>
	<brief_summary>The general aim trial determine efficacy ( measure change baseline end maintenance phase total score Unified Parkinsons Disease Rating Scale Parts II III combine ) , safety , tolerability pramipexole ER , daily dose 0.375 milligram 4.5 milligram day , comparison placebo , Levodopa combine Dopa-Decarboxylase-inhibitor treat Parkinson patient advance Parkinsons Disease motor fluctuation . In addition , numerical comparison efficacy pramipexole extend release versus pramipexole immediate release do . The efficacy pramipexole immediate release also compare placebo , assay sensitivity .</brief_summary>
	<brief_title>Pivotal Study Advanced Parkinsons Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Male female patient advance idiopathic Parkinsons disease confirm least two follow sign : rest tremor , bradykinesia , rigidity . 2 . Parkinsons disease diagnose least 2 year . 3 . Patients 30 year age old time diagnosis . 4 . Modified Hoehn Yahr stage 2 4 ontime . 5 . Treatment standard control release Levodopa combine DopaDecarboxylaseinhibitor , Levodopa combine DopaDecarboxylaseinhibitor/entacapone , optimise dose accord investigator judgement , dose stable least 4 week prior baseline visit . 6 . Motor fluctuation , least 2 cumulative hour offtime every day wake hour ( document patient diary complete 2 consecutive day baseline visit ) . 7 . Patient willing able comply schedule visit , treatment plan , laboratory test study procedure . In particular , training , document baseline visit patient able recognise offtime ontime period wake hour patient ( family member guardian ) able record accurately patient diary . 8 . Signed informed consent obtain study procedure carry ( accordance International Conference HarmonisationGood Clinical Practice guideline local legislation ) . 1 . Atypical parkinsonian syndrome due drug , metabolic disorder , encephalitis degenerative disease 2 . Dementia , define MiniMental State Exam score &lt; 24 screen visit 3 . Any psychiatric disorder accord Diagnostic Statistical Manual Mental Disorders 4th edition criterion could prevent compliance completion study and/or put patient risk he/she take part study 4 . History psychosis , except history drug induce hallucination 5 . History deep brain stimulation 6 . Clinically significant Electrocardiogram abnormality screen visit 7 . Clinically significant hypotension and/or symptomatic orthostatic hypotension screen baseline visit 8 . Malignant melanoma history previously treat malignant melanoma 9 . Any clinically significant disease , whether treat , could put patient risk could prevent compliance completion study 10 . Pregnancy breastfeed 11 . Sexually active female childbearing potential use medically approve method birth control least one month prior screen visit throughout study period 12 . Serum level Aspartate Aminotransferase ( Serum GlutamicOxaloacetic Transaminase ) , Alanine Aminotransferase ( Serum Glutamic Pyruvic Transaminase ) , alkaline phosphatase bilirubin &gt; 2 Upper Limit Normal 13 . Patients creatinine clearance &lt; 50 millilitres/minute 14 . Any dopamine agonist ( include pramipexole ) within 4 week prior baseline visit 15 . Any medication central dopaminergic antagonist activity within 4 week prior baseline visit 16 . Any following drug within 4 week prior baseline visit : methylphenidate , cinnarizine , amphetamines 17 . Flunarizine within 3 month prior baseline visit 18 . Known hypersensitivity pramipexole excipients 19 . Drug abuse accord investigator judgement , within 2 year prior screen 20 . Participation investigational drug study , use investigational drug within one month five time halflife investigational drug ( whichever longer ) prior baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>32 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>